SARS-CoV-2 Lineage B.1.1.529; Omicron Variant CF (Heat Inactivated) (1 mL) -  Log in for Price

SARS-CoV-2 Lineage B.1.1.529; Omicron Variant CF (Heat Inactivated) (1 mL)

Catalog# 0810642CFHI

For the purchase of our BSL2 or BSL3 level products the Laboratories Biosafety Level must be consistent with the products requirement. Please complete our Laboratory Biosafety Level Acknowledgement Form and submit it to [email protected] with a reference to your purchase order. Contact our trusted team today if you have any questions about SARS-CoV-2 Lineage B.1.1.529; Omicron Variant CF.

Learn More

For Research Use Only. Not for use in Diagnostic Procedures.

More Information

SARS-Related Coronavirus 2 Lineage B.1.1.529; Omicron Variant (Isolate: hCoV-19/USA/MDHP20874/2021) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MDHP20874/2021 was isolated from a nasal swab from a human as part of surveillance testing, on November 27, 2021, in Maryland, USA. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/MD-HP20874/2021 is assigned lineage B.1.1.529 and GISAID clade GR using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. Each frozen aliquot contains 1 mL of heat inactivated viral culture fluid. The pre-inactivation titer was determined from an infectious aliquot. Viral inactivation is verified after heat inactivation by the absence of viral growth in tissue culture-based infectivity assays.

Intended Use

Heat inactivated SARS-Related Coronavirus 2 Lineage B.1.1.529 viral culture fluids are sold as consumable testing materials. The suitability and performance characteristics should be determined by your laboratory for each intended usage.

These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

Welcome To